As many as 50 percent of human cancer cases -- across a wide variety of tissues -- involve defects in a common cellular growth signaling pathway. These defects have so far defied most attempts to ...

In 1980 I was recruited to the Institute of Cancer Research (ICR) by its new director, Robin Weiss. After seven years as a postdoctoral fellow, at last I was a tenure-track faculty member and anxious ...

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...

Despite the crucial role of RAF kinases in cell signaling and disease, we still lack a complete understanding of their regulation. Heterodimerization of RAF kinases as well as dephosphorylation of a ...

Scientists report that a recently identified molecule functions as a molecular switch that influences the activity of key signaling molecules by restricting the location of the activated molecules ...

The initiating oncogenic event in half of human lung adenocarcinomas is still unknown, a fact that complicates the development of selective targeted therapies. Researchers have demonstrated that the ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--REVOLUTION Medicines, Inc. today announced dosing of the first patient in a Phase 1, open-label, monotherapy dose-escalation and expansion study of RMC-4630, the ...

NORTH CHICAGO, Ill. and BEIJING, June 1, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical ...

Colon cancer cells with the cell nuclei stained red and the protein E-cadherin stained green. Credit: NCI Center for Cancer Research. As many as 50 percent of human cancer cases — across a wide ...

The initiating oncogenic event in almost half of human lung adenocarcinomas is still unknown, a fact that complicates the development of selective targeted therapies. Yet these tumours harbour a ...